A group of inventors have presently speak about the success of Vaginal ring , a great invention for protecting women from the effect of HIV.
New researches has found that women who used vaginal ring with an antiviral drug have very little chance of AIDS. Scientists say women who inserted a vaginal ring of silicon, coated with an anti AIDS drug once a month were almost protected against HIV infection.
The ring has been planned to give women a cautious way to protect themselves from infection in situations where they may not be able to refuse sex or demand that a man use a condom. When the flexible ring is inserted into the vagina, it securely frees a drug called dapivirine, which can help to protect the virus from infecting cells.
Every vaginal ring consists of 25 mg of the ARV dapivirine and about 4 mg of the medication gets released over the course of the month. The monthly vaginal ring is meant to be used for a month at a time, and women can easily insert and remove it on their own.
The initial researches showed it could be very effective if women really used it properly. In the ASPIRE study, which was a Phase III trial, researchers recruited 2,629 women ages 18-45 from Malawi, Uganda, South Africa and Zimbabwe, and divided them into two groups. Women in the first group were assigned to use the dapirivine ring;while those in the other group were given a placebo ring to use that contained no medication. Later studies were designed to see if women could be encouraged to use it consistently and whether it worked better if they did so. The ring worked better for women aged between 25-40 years. Researchers also tell younger women who got little to no benefit simply didn't use the device properly.
The scientists of this study told about the result of vaginal ring in the International AIDS Conference in Durban, South Africa. Research results are also being presented at the Retrovirus Conference in Boston. Generally woman’s risk of catching the human immunodeficiency virus(HIV) was cut by 60 percent, the team found. Women who used it the most; mostly older women reduced the risk by at least 75- 80 percent.
“Adherence to HIV prevention strategies is not always perfect, and we knew that not all women used the ring consistently, sowed developed an analysis to explore the degree of HIV protection that was associated with more consistent use,” explained Elizabeth R. Brown, Sc.D., from the Fred Hutchinson Cancer Research Center and University of Washington in Seattle. “Across all analyses we saw high adherence was associated with significantly better HIV protection.”
“We are encouraged by these new analyses, which further support that the dapivirine ring could be an important option for women who urgently need new tools to protect themselves from HIV,” said Dr. Zeda Rosenberg, chief executive officer of the IPM, the developer as well as the regulatory sponsor of the vaginal ring.
Dr.R. Brown and Dr. Zeda Rosenberg also told that the new results are very encouraging; even further analysis is required to validate the current outcome.
We are hoping for the best and final approval of this new invention to protect women from the curse of AIDS .